FDA approves first targeted drug for acute myelogenous leukaemia

Nature Reviews Drug Discovery 16, 375 (2017). doi:10.1038/nrd.2017.110 Author: Asher Mullard The FDA approved Novartis's FLT3 inhibitor midostaurin for acute myeloid leukaemia (AML). The multikinase inhibitor is the first targeted treatment for AML, and the first new FDA approval for AML in decades.The FLT3 kinase is mutated in around one-third of AML patients, and
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research